Please ensure Javascript is enabled for purposes of website accessibility

Why OPKO Health Shares Were Up 10% Today

By Todd Campbell - May 14, 2020 at 5:43PM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

The company is rolling out a new COVID-19 testing program for businesses.

What happened

After announcing it has launched a COVID-19 screening program to help employers make return-to-work decisions for employees, OPKO Health (OPK -0.55%) saw its shares close the day up more than 10% on Thursday.  

So what

OPKO Health's BioReference Labs has been assisting healthcare providers with COVID-19 testing services since mid-March. On Monday, management expanded its COVID-19 product platform with the launch of an antibody test that can determine if someone has been exposed to the virus, and on Wednesday, the healthcare company unveiled services designed to inform business decisions relating to employees.

Swab and test tube held by lab technician

Image source: Getty Images.

Specifically, its BioReference employer solution will allow employees to register for antibody testing online. It also provides for on-site testing and processing, with online access to testing results. BioReference is also offering pop-up testing sites that businesses can use, with the first of these locations opening on Friday in Livingston, New Jersey.

The move positions the company to capture a growing share of what is becoming a significant opportunity: increasing demand for testing services. Since March, BioReference Labs has performed hundreds of thousands of tests, and its capacity has reached 35,000 tests daily. 

Now what

OPKO's revenue was $211.5 million in the first quarter, which was down 4.9% year over year because early testing capacity wasn't able to offset declining lab-services demand from doctor-office visits caused by shelter-in-place orders. It's unclear if COVID-19 testing, including antibody testing, will be able to overcome the headwind this quarter, but management has said it will soon be able to process 400,000 antibody tests per day. 

An increase in COVID-19 business is particularly important to OPKO Health, because it posted losses of $59.1 million last quarter, and it's arguably financially hamstrung given the company only had $35 million in cash on its balance sheet exiting March. The company does have wiggle room courtesy of a $100 million credit facility from its founder, Phillip Frost, but it could certainly benefit if COVID-19 testing demand can keep it from tapping that financing.

Todd Campbell has no position in any of the stocks mentioned. His clients may have positions in the companies mentioned. The Motley Fool has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy.

Invest Smarter with The Motley Fool

Join Over 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Stocks Mentioned

OPKO Health, Inc. Stock Quote
OPKO Health, Inc.
OPK
$2.69 (-0.55%) $0.01

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning analyst team.

Stock Advisor Returns
390%
 
S&P 500 Returns
125%

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 08/11/2022.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.